<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="807">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355143</url>
  </required_header>
  <id_info>
    <org_study_id>20-000685</org_study_id>
    <nct_id>NCT04355143</nct_id>
  </id_info>
  <brief_title>Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)</brief_title>
  <acronym>COLHEART-19</acronym>
  <official_title>Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per
      UCLA treating physicians versus current care per UCLA treating physicians alone (control
      arm). Importantly, this adaptive trial design allows for patients in either study arm to
      receive other investigational drugs for COVID-19 as new science emerges.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random assignment to study arms in a 1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)</measure>
    <time_frame>90 Days</time_frame>
    <description>Number of participants experiencing any of the following: All-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta (peak minus baseline) troponin level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized</time_frame>
    <description>Change from initial troponin level to maximum level of troponin among measures taken during hospitalization and at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (baseline to peak) brain natriuretic peptide (BNP) level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized</time_frame>
    <description>Change from baseline BNP level (Day 1) to maximum level of BNP among measures taken during hospitalization and at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) on echocardiography</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>Number of participants experiencing LVEF of &lt; 50% on echocardiogram with failure to show an improvement of â‰¥ 5% at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (peak minus baseline) D-Dimer inflammatory biomarker level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized</time_frame>
    <description>D-Dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, so named because it contains two D fragments of the fibrin protein joined by a cross-link</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to primary endpoint</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical ventilation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical circulatory support (MCS)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants released and re-admitted to the hospital within 90 days of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current care alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current care per UCLA physicians alone (control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Tablets</intervention_name>
    <description>COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.</description>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <other_name>COLCRYS</other_name>
    <other_name>AR 374</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Current care per UCLA treating physicians</intervention_name>
    <description>Current care</description>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <arm_group_label>Current care alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 infection by polymerase chain reaction

          -  Cardiac injury, including any of the following:

               -  Elevated troponin level

               -  Elevated B-type natriuretic peptide (BNP) level

               -  New ischemic or arrhythmogenic changes on ECG/telemetry

               -  New decrease in left ventricular ejection fraction (LVEF) or new pericardial
                  effusion on echocardiogram

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Pregnancy, breastfeeding mothers, and women of childbearing age who are unable to use
             2 forms of contraception, which includes:

               -  Intrauterine devices (IUD), contraceptive implants, or tubal sterilization

               -  Hormone methods with a barrier method

               -  Two barrier methods

               -  If a partner's vasectomy is the chosen method of contraception, a hormone or
                  barrier method must also be used in conjunction

          -  Co-administration of CYPA3A4 and P-glycoprotein (P-gp) transport system inhibitors

          -  Concurrent use of strong CYP3A4 or P-gp inhibitors in patients with renal or hepatic
             impairment;

          -  Severe hematologic or neuaromuscular disorders

          -  Severe renal impairmant with concomitant hepatic impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Ardehali, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir B Rabbani, MD</last_name>
    <phone>310-517-8578</phone>
    <email>arabbani@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Ardehali, MD, PhD</last_name>
    <phone>310-825-9011</phone>
    <email>rardehali@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Santa Monica Hospital</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

